Central Nervous System Therapeutics Market Size & Share 2023 to 2032
Market Size by Disease (Degenerative, Mental health, Neurovascular, Infectious), Drug type (Antidepressant, Immunomodulatory drug, Anti-epileptics), Distribution Channel.
Report ID: GMI6097
|
Published Date: June 2023
|
Report Format: PDF
Download Free PDF
Authors:
Monali Tayade, Jignesh Rawal
Central Nervous System Therapeutics Market Size
Central Nervous System Therapeutics Market size was anticipated to be worth USD 110.4 billion in 2022 and is expected to reach USD 238.8 billion by 2032, increasing at an 8% CAGR 2032. The rising prevalence of CNS disorders, such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, and depression drives the demand for effective CNS therapeutics.
Central Nervous System Therapeutics Market Key Takeaways
Market Size & Growth
Key Market Drivers
Challenges
Moreover, technological advancements in treatment approaches, increasing adoption of novel drug delivery systems, neuromodulation techniques, and personalized medicine. These advancements allow for more precise and effective drug delivery to the CNS, enhancing therapeutic outcomes and minimizing side effects.
COVID-19 Impact
The COVID-19 pandemic had a significant impact on the central nervous system therapeutics market. The pandemic has led to a decrease in the number of patients being treated for CNS disorders, as well as a decrease in the number of new CNS drug approvals.
The healthcare system was overwhelmed by the unpredicted demand of managing COVID-19 patients, leading to a shift in priorities and resources. Elective procedures, including those related to CNS disorders, were postponed in 2020. Many people have been reluctant to go to the doctor during the pandemic, for fear of contracting COVID-19. This has led to a decrease in the number of patients being diagnosed with CNS disorders, as well as a decrease in the number of patients being treated for these disorders.
Moreover, the pandemic disrupted ongoing clinical trials and research activities related to CNS therapeutics. Many trials were halted or postponed due to restrictions on patient recruitment, limited access to healthcare facilities, and prioritization of COVID-19 research. This led to delays in the development and regulatory approval of new CNS therapies.
However, pandemic resulted in increased stress, anxiety, depression, and other mental health conditions. This created a higher demand for CNS therapeutics related to mental health disorders. Telemedicine and virtual care solutions were utilized to provide remote mental health support and prescriptions for CNS medications. This shift is expected to have long-term implications for the delivery of CNS therapies.
Central Nervous System Therapeutics Market Trends
The market is experiencing several notable trends that are shaping its progression and development. Some key trends in the industry includes increasing advancements in precision medicine, increasing focus on developing therapeutics that not only alleviate symptoms but also target the underlying mechanisms of CNS disorders, rise of digital therapeutics and remote monitoring, integration of artificial intelligence in healthcare, and focus on combination therapies.
Central Nervous System Therapeutics Market Analysis
Based on disease, the central nervous system therapeutics market is segmented as degenerative disorders, mental health, neurovascular diseases, autoimmune and inflammatory diseases, infectious diseases, CNS cancer, genetic diseases, CNS trauma, substance abuse disorders, and other diseases. In 2022, the degenerative disorders segment accounted for the largest share of 37.7% in industry. Degenerative disorders such as alzheimer's disease, parkinson's disease, and huntington's disease are often associated with aging. As the global population continues to age, the prevalence of these disorders is increasing.
Based on drug type, the central nervous system therapeutics market is segmented as antidepressant, immunomodulatory drug, anti-epileptics, analgesics, anti-parkinson drugs, anesthetics, decarboxylase inhibitors, dopamine agonists, interferons, and other drug classes. The antidepressant segment held dominant market share of around 25.5% in 2022 and is expected to grow at a significant pace of 8.3% by 2032. The increasing prevalence of mental health disorders such as depression, anxiety, increased awareness and diagnosis about these diseases, improved access to mental health services, and effectiveness and efficacy of antidepressants in the management of various CNS disorders.
The pharmaceutical industry has made significant advancements in the development of antidepressant drugs. Newer classes of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and atypical antidepressants, offer improved efficacy and tolerability profiles compared to older generations of medications.
Based on distribution channel, the central nervous system therapeutics market is segmented as hospital pharmacies, retail pharmacies, and other distribution channels. The hospital pharmacies segment held a dominant market share of 48.6% in 2022 and is expected to grow at a CAGR of 7.9% by 2032. Hospitals serve as a primary care setting for patients with acute and severe CNS conditions, such as strokes, traumatic brain injuries, seizures, and psychiatric emergencies.
North America central nervous system therapeutics market is expected to reach USD 113.3 billion in 2032 with a CAGR of 7.9% by 2032. North America experiences a substantial burden of CNS disorders, including neurodegenerative diseases, mental health disorders, epilepsy, and multiple sclerosis. The prevalence of these conditions drives the demand for effective CNS therapeutics.
Moreover, the region's focus on technological advancements in healthcare contributes to the development of innovative CNS therapeutics. North America is at the forefront of research and development in areas such as precision medicine, gene therapy, digital health, and neuroimaging.
Central Nervous System Therapeutics Market Share
Some of the major market players operating in the central nervous system therapeutics market are
Central Nervous System Therapeutics Industry News:
The central nervous system therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032, for the following segments:
Click here to Buy Section of this Report
By Disease, 2018 - 2032 (USD Million)
By Drug type, 2018 - 2032 (USD Million)
By Distribution Channel, 2018 - 2032 (USD Million)
The above information is provided for the following regions and countries:
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →